Flonoltinib

• Description :

  Flonoltinib is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib has anti-cancer activity[1].

• CAS Number :

  [2387765-27-5]

• Product Name Alternative :

  JAK2/FLT3-IN-1

• UNSPSC :

  12352005

• Target :

  Apoptosis; FLT3; JAK

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/flonoltinib.html

• Concentration :

  10mM

• Purity :

  99.48

• Solubility :

  DMSO : 35 mg/mL (ultrasonic)

• Smiles :

  OCCN(C1CCN(C2=CC=C(NC3=NC=C(C)C(C4=CN(C(C)C)N=C4)=N3)C=C2F)CC1)C

• Molecular Formula :

  C25H34FN7O

• Molecular Weight :

  467.58

• References & Citations :

  [1]Yang T, et al. Discovery of Potent and Orally Effective Dual JAK2/FLT3 Inhibitors for the Treatment of AcuteMyelogenous Leukemia and Myeloproliferative Neoplasms. J Med Chem. 2019 Oct 31.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  JAK1; JAK2; JAK3